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Class II transactivator (CIITA) is a transcriptional coactivator that regulates γ-interferon-
activated transcription of Major Histocompatibility Complex (MHC) class I and II genes. As
such, it plays a critical role in immune responses: CIITA deficiency results in aberrant MHC
gene expression and consequently in autoimmune diseases such as Type II bare lympho-
cyte syndrome. Although CIITA does not bind DNA directly, it regulates MHC transcription
in two distinct ways – as a transcriptional activator and as a general transcription factor. As
an activator, CIITA nucleates an enhanceosome consisting of the DNA binding transcription
factors RFX, cyclic AMP response element binding protein, and NF-Y. As a general tran-
scription factor, CIITA functionally replaces the TFIID component, TAF1. Like TAF1, CIITA
possesses acetyltransferase (AT) and kinase activities, both of which contribute to proper
transcription of MHC class I and II genes. The substrate specificity and regulation of the
CIITA AT and kinase activities also parallel those of TAF1. In addition, CIITA is tightly reg-
ulated by its various regulatory domains that undergo phosphorylation and influence its
targeted localization.Thus, a complex picture of the mechanisms regulating CIITA function
is emerging suggesting that CIITA has dual roles in transcriptional regulation which are
summarized in this review.
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The class II transactivator (CIITA) is a master regulator of major
histocompatibility complex (MHC) gene expression. It induces de
novo transcription of MHC class II genes and enhances constitu-
tive MHC class I gene expression. The role of CIITA in regulating
MHC gene transcription is well established: CIITA deficiency or
aberrant expression is linked to the Type II bare lymphocyte syn-
drome and to cancer, respectively (1, 2). Although CIITA has been
primarily characterized as a transcriptional regulator of MHC
genes, it also regulates transcription of over 60 immunologi-
cally important genes, including interleukin 4 (IL-4), IL-10, and
a variety of thyroid-specific genes (3, 4). Despite the important
role of CIITA in regulating expression of these genes, the actual
mechanisms by which it functions are still being unraveled. Early
studies established that CIITA is a coactivator that nucleates the
formation of an enhanceosome with transcription factors bind-
ing to enhancer elements in the upstream regions of the MHC
genes (5, 6). In addition, more recent studies from our lab have
demonstrated that it also functions as a component of the basal
transcriptional machinery (7–9). Here we review the two dis-
tinct mechanisms by which CIITA regulates transcription of MHC
class I and II genes and speculate on how these activities may be
interconnected.
CIITA BELONGS TO THE FAMILY OF NLR/CATERPILLER
PROTEINS
The members of the NLR/CATERPILLER family of proteins are
defined by their structures which include both a nucleotide bind-
ing domain (NBD) and a C-terminal leucine rich region (LRR)
(10). Of the nearly two dozen genes within the family, many encode
proteins that mediate inflammatory responses and whose aberrant
expression has been correlated with a variety of diseases (11). Of
these, only CIITA is a critical mediator of adaptive immunity. Con-
stitutive expression of CIITA is limited to antigen presenting cells.
However,γ-interferon exposure induces de novo CIITA expression
in most cell types (12, 13). Its activity is known to be modulated
by several posttranslational modifications including phosphory-
lation, ubiquitination, acetylation, and deacetylation (14). CIITA
can also self-associate and oligomerize (15, 16). CIITA activity
is further modulated by its cellular localization: the GTP bind-
ing domain (GBD) of CIITA regulates its shuttling between the
nucleus and cytoplasm (17, 18).
Class II transactivator consists of a series of regulatory domains
that include an activation domain (AD), an acetyltransferase (AT)
domain, a proline/serine/threonine (PST) domain, a GBD and
finally, the canonical LRR domain common to all NLR proteins.
The CIITA AD domain binds to general transcription factors and
the CREB-binding protein (CBP), leading to activation of the
MHC class II promoter and repression of the IL-4 promoter (19,
20). This domain also partially overlaps the region required for the
AT activity of CIITA (7). The role of the PST domain, which while
essential for CIITA function, remains unknown (21). The LRR
domain, which interacts with the GBD, is known to play an impor-
tant role in CIITA movement into the nucleus and in regulating
its transactivation function (15, 21, 22). The GBD domain, which
is perhaps the best studied among the CIITA domains, has been
shown to be the site of interaction of several DNA binding transac-
tivators (23). The GBD regulates translocation of CIITA: mutation
or deletion of the GBD results in increased nuclear export, suggest-
ing that it is a negative regulator of CIITA nuclear export (18). Two
nuclear localization signals have been mapped to the N-terminal
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domain, as well as an additional one in the C-terminus (18). CIITA
also contains two LxxLL motifs which are crucial for the transacti-
vation function and self-association of CIITA (24). In addition to
these multifunctional domains, CIITA also contains two degrons
in the AD and PST domains respectively. These degrons signal the
rapid degradation of CIITA through the ubiquitin-proteasome
pathway, and are responsible for the instability and short half-
life of CIITA (~30 min) (25). CIITA function is also regulated
through its oligomerization, which has been shown to be medi-
ated by amino acids 253–410 (16). Each of the domains and regions
listed above are also the targets of multiple post translational mod-
ifications which control their function (14). The expression of the
CIITA gene itself is regulated by a complex mechanism involving
four promoters and five enhancers that combine to form a dynamic
chromatin structure (26, 27). Thus, CIITA is an extremely com-
plex, unstable, and short lived protein, suggesting that its presence
and function are tightly regulated.
CIITA FUNCTIONS AS A TRANSACTIVATOR BY NUCLEATING
AN ENHANCEOSOME
The role of CIITA as a central component of an enhanceosome
has been characterized primarily for the MHC genes. MHC class
II genes are transcriptionally controlled via conserved cis-acting
elements in their promoters. These elements, named the W/S,
X, X2, and Y boxes interact with specific trans-activating DNA
binding factors to regulate MHC transcription either positively or
negatively (28). The DNA binding factors involved, namely RFX
(a hetero-multimer consisting of subunits RFX5, RFX-ANK, and
RFX-AP), cyclic AMP response element binding protein (CREB),
and NF-Y (A, B, and C), bind directly to the X, X2, and Y boxes
respectively. These factors are constitutively expressed but their
binding to the class II gene is not sufficient to support expression
(29). CIITA interacts with each of these DNA binding factors (30).
Those interactions depend on distinct structural domains within
CIITA. CIITA transactivator function is dependent on the AD, PST,
GBD, and LRR domains within its primary protein structure. RFX-
ANK and NF-YC bind to the N-terminal acidic AD, whereas the
remaining trans-activating factors interact with the GBD (23). The
interaction of CIITA with the DNA-bound transcription factors
serves to form a transcriptionally active complex, or enhanceo-
some (5). Importantly, the cognate DNA binding sites are spaced
in a manner that supports the formation of an enhanceosome
complex anchored by CIITA (31).
Within the enhanceosome, CIITA functions in the recruit-
ment of various histone modifying enzymes, both activating and
repressive. During MHC gene activation, CIITA recruits histone
modifying enzymes such as the ATs p300, CBP, and the p300/CBP-
associated factor (PCAF), as well as the methyltransferase CARM1
which function to support active transcription (32). In contrast,
during MHC gene silencing, CIITA and RFX recruit and bind his-
tone deacetylases HDAC1, HDAC2, and HDAC4 (31). CIITA also
interacts with chromatin remodeling factors, such as BRG1 (33),
and other coactivactors such as SRC-1 (32). Thus, while CIITA
does not directly bind DNA, it serves to nucleate and coordi-
nate the various transcription factors and chromatin modifying
enzymes that are necessary to support transcription of the class I
and II genes.
The concept of a CIITA-nucleated enhanceosome fits well
with the regulation of MHC class I and II transcription, and
is supported by considerable circumstantial evidence. Such evi-
dence includes the demonstration of direct interaction between
CIITA and the other components of the predicted enhanceo-
some (5). However, CIITA also transactivates many genes that
may not possess the cis-elements and trans-factors that are found
on MHC genes (3). This raises the possibility that CIITA may
also have a more direct function in transcription besides nucleat-
ing an enhanceosome. Indeed, as will be discussed below, CIITA
functions as a component of the basal transcription machinery.
CIITA FUNCTIONS AS A GENERAL TRANSCRIPTION FACTOR
AND FUNCTIONAL HOMOLOG OF TAF1
The basal transcriptional machinery requires the assembly on the
core promoter of a pre-initiation complex (PIC) that plays a cen-
tral role in regulating transcription initiation. PIC assembly is
initiated by the binding of the TFIID general transcription fac-
tor complex – composed of the TATA-binding protein (TBP) and
a set of TBP-associated factors (TAFs) – to the core promoter (34).
The largest factor in the TFIID complex, TAF1, has AT and kinase
activities both of which are essential for transcription initiation
(35, 36). In early studies from our lab, it was demonstrated that
constitutive transcription of MHC class I genes depends on the AT
activity of TAF1: MHC class I expression was abrogated at restric-
tive temperatures in TAF1 temperature-sensitive mutants. In con-
trast, CIITA-activated transcription of MHC genes was unaffected
under these conditions, and thus independent of TAF1 function
(37). This finding led to our discovery that CIITA, like TAF1, has
an intrinsic AT activity and can bypass the requirement for TAF1
(7). Based on these findings, we proposed that CIITA functions as
a general transcription factor that can substitute for TAF1 function
during γ-interferon-activated MHC transcription (38).
Consistent with the model that CIITA is a general transcription
factor that assembles a TFIID-like complex, CIITA is known to
recruit and directly interact with components of the TFIID com-
plex, including TBP, TAF6, and TAF9, as well as PTEFb and TFIIB
which are components of the PIC (39, 40). Further supporting
this model, we found that CIITA interacts with the TFIID compo-
nent TAF7 (8) which acts as a check-point regulator of constitutive
class I transcription initiation by inhibiting TAF1 AT activity (41).
TAF7 binds directly to the region encompassing the AT domain of
CIITA. Importantly, the binding of TAF7 to CIITA in vitro inhibits
both its AT activity and transcription. In vivo knock-down of TAF7
resulted in a significant increase in CIITA-activated MHC class I
gene expression (8). Taken together, these findings suggested that
CIITA is a functional homolog of TAF1.
Further evidence for the parallels between CIITA and TAF1
came from the finding that CIITA, like TAF1, is a kinase (9).
In the canonical TFIID complex, TAF1 is associated with and
inhibited by TAF7 until PIC assembly is complete. Transcription
initiation requires the release of TAF7 from TAF1, thereby reveal-
ing TAF1’s essential AT activity. The release is mediated by TAF1
autophosphorylation by its intrinsic kinase activity, which is essen-
tial for initiating transcription (42). Interestingly, although TAF1
also phosphorylates TAF7, this does not cause the release of TAF7
from the TFIID complex. Rather, it modulates the subsequent
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regulation of TFIIH, BRD4, and PTEFb transcription factors by
TAF7 (43, 44). The finding that CIITA AT activity bypasses the
requirement for TAF1 during activated MHC class I transcrip-
tion and that TAF7 inhibits this activity suggested that CIITA also
might have a kinase activity responsible for dissociating TAF7.
Indeed, we recently found that CIITA has intrinsic kinase activity
(9). CIITA, like TAF1, autophosphorylates. This autophospho-
rylation prevents the binding of TAF7 which would otherwise
inhibit its AT activity. CIITA phosphorylates TAF7, although at
sites distinct from those phosphorylated by TAF1 (9). It remains
to be determined whether TAF7 phosphorylation by CIITA, like by
TAF1, modulates the subsequent regulation of TFIIH and PTEFb
by TAF7.
Similar to TAF1, the AT activity of CIITA was identified by its
ability to acetylate histones in vitro (7). However, the actual in vivo
substrate(s) for both CIITA and TAF1 remain to be defined. This
leaves open the possibility that CIITA acetylates any of its numer-
ous interacting partners in vivo. Additionally, the AT activity of
CIITA is modulated by its own GBD; the binding of GTP at this site
increases AT activity and nuclear localization of CIITA (7). Acety-
lation of CIITA on its N-terminal nuclear localization domain by
PCAF is also known to be a signal for its nuclear localization (45).
However, the loss of its AT domain does not affect CIITA’s nuclear
localization (18). Thus, while it is established that the AT activity
of CIITA is undoubtedly required for its function in transcrip-
tional regulation, many questions remain regarding the targets of
this activity, the complexity of its regulation both directly by trans
factors and indirectly by other regulatory domains on CIITA.
Class II transactivator function is also regulated by phosphory-
lation, as has been well documented (16, 46, 47). CIITA is known to
be phosphorylated by PKA, PKC, GSK3, CK1, ERK1/2, and CKII
kinases at various sites spanning its AT, PST, and LRR domains
(14). These phosphorylation events are known to regulate its trans-
activation function, nuclear localization, oligomerization, and its
ability to interact with DNA binding transactivators. The newly
discovered kinase activity of CIITA adds an additional layer of
complexity to the functional mechanisms by which CIITA oper-
ates. The kinase activity of CIITA and its ability to autophosphory-
late are thus likely to have significant ramifications on its function.
Indeed, we found that autophosphorylation of CIITA enhances
its AT activity in vitro, suggesting that the two enzymatic activi-
ties of CIITA are interconnected. In contrast to the AT activity of
CIITA, at least three independent substrates for CIITA kinase activ-
ity have been found thus far including TAF7, Histone H2B, and
the TFIIF component RAP74 (9). While CIITA autophosphoryla-
tion regulates its ability to interact with TAF7 and consequently
its AT activity, the purpose of TAF7 phosphorylation by CIITA
is yet to be discovered. By analogy with TAF1 (44), we speculate
that it modulates TAF7 binding to its downstream targets, BRD4,
PTEFb, and TFIIH. RAP74 phosphorylation by TAF1 is thought
to help in coordinating the functions of different components of
the pre-initiation complex (36). Whether CIITA phosphorylation
of RAP74 serves the same purpose remains to be seen. Similarly,
the phosphorylation of Histone H2B at Ser36 has been demon-
strated to play a significant role in regulating transcription during
cell cycle progression and stress response (48, 49). Therefore, the
ability of CIITA to phosphorylate Histone H2B Ser36 (9) supports
the idea that it has a role beyond its known function in regulating
MHC genes. The substrate specificities of CIITA kinase activity,
although very similar to those of TAF1, are distinct. CIITA phos-
phorylates TAF7 at a different site and phosphorylates all histones
unlike TAF1 (9). We speculate that the distinct nature of CIITA
kinase activity suggests that it may have other substrates, possibly
in the enhanceosome complex that it nucleates.
INTEGRATING THE DUAL FUNCTIONS OF CIITA: A MODEL
Although CIITA has no obvious structural homology with TAF1,
it has remarkable functional parallels. Like TAF1, CIITA associates
with general transcription factors to form a TFIID-like complex
(8, 39, 40). Both CIITA and TAF1 have AT activity that is essen-
tial for transcription (7, 35, 41); both AT activities are regulated
by TAF7 (8, 41). CIITA and TAF1 both have kinase activity that
results in autophosphorylation leading to TAF7 dissociation (9, 36,
42). Taken together, these findings demonstrate that CIITA func-
tions as a general transcription factor and functional homolog of
TAF1, independent of its role as a coactivator that nucleates an
enhanceosome. The dual functionality of CIITA, as a coactivator
and a general transcription factor, leads to the question of how
these two disparate functions are coordinated during MHC gene
regulation. We propose the following model (Figure 1).
Following induction by γ-interferon, CIITA nucleates the for-
mation of an enhanceosome through its interaction with transac-
tivators that are constitutively bound to conserved DNA elements
within the extended promoters of MHC class I and II (Figure 1A).
We speculate that within the enhanceosome, CIITA may partici-
pate in chromatin remodeling, along with the histone modifying
enzymes it recruits to the enhanceosome. Indeed, CIITA efficiently
acetylates histones H3 and H4 (7). The acetylations may serve
to maintain the MHC class I- and II-associated chromatin in a
transcriptionally active conformation. Alternatively, within the
enhanceosome, CIITA may acetylate any one of its interacting
partners: the binding site on CIITA for many of the CIITA inter-
acting partners in the MHC II enhanceosome (e.g., RFX-ANK and
NF-YC) maps to the N-terminal α-helical acidic domain between
amino acids 58 and 94 (23), which is immediately adjacent to the
CIITA AT domain between amino acids 94 and 132 (7). Whether
these factors are substrates of the AT activity or whether their
binding to CIITA within the context of the enhanceosome acti-
vates or represses AT activity remain intriguing questions. CIITA
also efficiently phosphorylates all four histones (9). Phosphoryla-
tion of H2B by CIITA has been mapped to Ser36 (9), an event that
leads to increased transcription and survival during cell stress (49).
Thus it is possible that CIITA’s enzymatic activities contribute to
its coactivator function.
We further speculate that the TFIID-like complex assembled by
CIITA is recruited to the promoters of MHC class I and II genes
by the CIITA-nucleated enhanceosome through dimerization of
the CIITA molecules contained within each complex (Figure 1B).
According to this model, following nucleation by CIITA, the
enhanceosome would interact with the TFIID-like CIITA complex
and deliver it to the downstream core promoter. The binding of the
TFIID-like CIITA complex to the core promoter would trigger the
assembly of a PIC. Once PIC assembly is complete, CIITA would
autophosphorylate, releasing TAF7 from the TFIID-like complex.
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FIGURE 1 | Proposed model for the dual roles of CIITA in MHC gene
transcription. (A)The induction of CIITA, in response to γ-interferon, leads to
the assembly of an enhanceosome through CIITA’s interactions with CREB
and the NF-Y and RFX transactivators associated with the X and Y box DNA
elements, respectively. In addition, CIITA interacts with chromatin modifying
(CM) enzymes, contributing to chromatin remodeling. (B) Independently,
CIITA recruits several components of the canonical TFIID complex, namely
TAF6/9, TAF7, and TBP. The CIITA in the TFIID-like complex is recruited to and
dimerizes with the CIITA present at the enhanceosome. TAF7 keeps the
acetyltransferase activity of CIITA in check during this process ( ). (C)The
arrival of other general transcription factors (GTFs) completes assembly of the
pre-initiation complex, leading to autophosphorylation of CIITA ( ). CIITA
autophosphorylation triggers the release of TAF7 and reveals the AT activity of
CIITA ( ), allowing transcription to initiate.
The release of TAF7 would relieve the inhibition of the AT activ-
ity associated with the CIITA in the TFIID-like complex. This AT
activity, like that of TAF1, is required for transcription initiation.
As noted above, CIITA also activates transcription of non-MHC
genes that do not support formation of enhanceosomes comprised
of NF-Y and RFX (3). We speculate that these promoters recruit
CIITA to the upstream regulatory regions of promoters through
its binding to a variety of other transcription factors. This CIITA,
by dimerization with CIITA in the TFIID-like complex is then able
to deliver it to the core promoter. Future experiments will test this
model.
The fact that CIITA is one of a family of NLR/CATERPILLER
proteins also raises the possibility that other members of the family
may have similar bi-functionality. Indeed, NLRC5, another NLR
family member, regulates MHC class I gene transcription (50).
NLRC5 domain structure is similar to that of CIITA; it has been
proposed to assemble an enhanceosome on MHC class I pro-
moters. It will be of interest to determine whether NLRC5 has
enzymatic activities and dual roles in transcription analogous to
those of CIITA.
CONCLUSION
Class II transactivator regulates transcription of both MHC and
non-MHC genes through its multiplicity of functions. It functions
as a transcriptional transactivator in assembling an enhanceosome
with transcription factors bound to the distal promoters of MHC
genes and as a general transcription factor and functional homolog
of TAF1 associated with the core promoter. While it is possible
that these CIITA functions are independent, the cross-regulation
of the AT and kinase activities of CIITA suggests that they are
interconnected. Thus, we speculate that CIITA initially assembles
an enhanceosome with DNA-bound transactivators, first recruit-
ing histone modifying enzymes and then a TFIID-like complex
containing CIITA that nucleates assembly of the PIC. Within the
PIC, CIITA functionally replaces TAF1 to initiate transcription.
As other substrates for the enzymatic activities of CIITA are dis-
covered in the future, it is likely that the complexity of CIITA
function will further increase. Which genes CIITA activates as a
basal transcription factor, and if this is determined by the presence
or absence of upstream nucleation sites for an enhanceosome, will
also be subjects for future research.
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